Hongo M, Sentianin E M, Tanaka N, Mao L, McKirnan M D, Clark R G, Won W, Chien K R, Ross J
Department of Medicine, University of California, San Diego, La Jolla 92093-0613, USA.
J Card Fail. 1998 Sep;4(3):213-24. doi: 10.1016/s1071-9164(98)80008-0.
Recombinant human growth hormone (rhGH) has shown beneficial effects on cardiac function after myocardial infarction (MI) in rats. High-dose angiotensin II (AT1) receptor blockade in normal rats inhibited the hypertrophic effect of growth hormone (GH), therefore we investigated whether GH effects after MI would be enhanced by giving it in sequence after remodeling had been inhibited by prior AT1 blockade (losartan, L).
Rats given losartan for 10 weeks after MI followed by rhGH for 2 weeks (2 mg/kg twice a day, GH plus losartan) were compared with rats given losartan for 10 weeks followed by placebo for 2 weeks (placebo plus losartan group) and with untreated controls (n = 17-20/group). Average MI sizes and left ventricular (LV) end diastolic (ED) dimensions (echocardiography) did not differ between groups. In GH and losartan, body weight (BW) was increased but left ventricular weight (LVW)/BW was reduced, and the LV fractional shortening and LV dP/dtmax (catheter tip micromanometer) were increased compared with the control group (20.3 vs 15.4% and 5579 vs 4699 mmHg/s, respectively, P < .05). The cardiac index also was significantly increased. In the placebo plus losartan group, the LVW/BW was also reduced and the cardiac index increased versus controls. Stroke volume was increased in GH plus losartan group compared with both placebo plus losartan and controls, and the systemic vascular resistance was significantly decreased only in the GH plus losartan group. The ED posterior wall thickness (noninfarcted wall) was increased in GH plus losartan compared with both control and placebo plus losartan. Left ventricular end diastolic pressure reduction was not significant in GH plus losartan group versus controls but was reduced in placebo plus losartan group, whereas LV relaxation (tau) was improved in both groups versus control rats. Thus, persistent remodeling effects caused by prior AT1 blockade undoubtedly contributed to some responses, but short-term GH given in sequence after chronic AT1 blockade had favorable actions on the failing heart and peripheral circulation by increasing LV wall thickness with partial reversal of unfavorable remodeling, lowering of vascular resistance, improvement of LV contractility, and enhanced LV systolic function and cardiac index relatively late after experimental MI.
重组人生长激素(rhGH)已显示对大鼠心肌梗死后(MI)的心脏功能有有益作用。正常大鼠中高剂量血管紧张素II(AT1)受体阻断可抑制生长激素(GH)的肥厚作用,因此我们研究了在MI后,在先使用AT1阻断剂(氯沙坦,L)抑制重塑后再依次给予GH,是否会增强GH的作用。
将MI后给予氯沙坦10周,随后给予rhGH 2周(2mg/kg,每日两次,GH加氯沙坦)的大鼠与给予氯沙坦10周,随后给予安慰剂2周的大鼠(安慰剂加氯沙坦组)及未治疗的对照组(每组n = 17 - 20)进行比较。各组间平均MI大小和左心室(LV)舒张末期(ED)直径(超声心动图)无差异。在GH加氯沙坦组中,体重(BW)增加,但左心室重量(LVW)/BW降低,与对照组相比,左心室缩短分数和LV dP/dtmax(导管尖端微测压计)增加(分别为20.3%对15.4%和5579对4699mmHg/s,P <.05)。心脏指数也显著增加。在安慰剂加氯沙坦组中,与对照组相比,LVW/BW也降低,心脏指数增加。与安慰剂加氯沙坦组和对照组相比,GH加氯沙坦组的每搏输出量增加,仅在GH加氯沙坦组全身血管阻力显著降低。与对照组和安慰剂加氯沙坦组相比,GH加氯沙坦组的ED后壁厚度(非梗死壁)增加。与对照组相比,GH加氯沙坦组左心室舒张末期压力降低不显著,但在安慰剂加氯沙坦组降低,而两组与对照大鼠相比左心室舒张(tau)均得到改善。因此,先前AT1阻断引起的持续性重塑作用无疑促成了一些反应,但在慢性AT1阻断后依次给予短期GH对衰竭心脏和外周循环有有利作用,通过增加LV壁厚度部分逆转不利重塑、降低血管阻力、改善LV收缩性,并在实验性MI后相对较晚增强LV收缩功能和心脏指数。